Longevity and Evidence-Based Interventions

Executive Summary

Current scientific consensus

Researchers today no longer regard ageing as an immutable fate, but as a biological process open to intervention. The geroscience hypothesis that binds the field together states that the molecular and cellular mechanisms driving ageing are shared across most chronic diseases (heart disease, cancer, dementia, diabetes); therefore, targeting ageing itself may delay many diseases simultaneously and compress the years spent in ill health late in life (Kennedy et al., 2014; López-Otín et al., 2023). The distinction at the centre of all this is between lifespan (the years lived) and healthspan (the years lived in good health): the goal is not merely more years, but more healthy years.

From the outset, three caveats that frame everything else must be stated plainly:

1. No drug, supplement or treatment has yet been proven to extend the lifespan of healthy people in a randomised controlled trial with mortality or disease endpoints. The strongest human evidence still belongs to ordinary lifestyle factors.
2. The most striking results come from short-lived animals (worms, flies, mice). Translation to humans often fails outright, or the effect shrinks dramatically. The NIA Interventions Testing Program has shown that the great majority of "promising" compounds do not extend lifespan even in mice under rigorous testing (Nadon et al., 2017).
3. Ageing biomarkers (e.g. epigenetic clocks) are research tools. They are not validated well enough to tell how fast an individual is ageing or whether an intervention is working — at least not yet.

Those with the strongest evidence

In conclusion: in 2026 the most reliable longevity strategy is unglamorous — fitness, muscle, metabolic health, sleep, dietary quality, not smoking, moderate or no alcohol, and strong social ties. Pharmacology is advancing rapidly; GLP-1 drugs are the most important recent development. Even so, for healthy people the drug and supplement space remains largely a bet built on surrogate endpoints.

The Biology of Ageing

The Hallmarks of Aging

The organising framework of the field is the "hallmarks of aging". First proposed as nine hallmarks (López-Otín et al., 2013), the framework was expanded to twelve in 2023 (López-Otín et al., 2023). A hallmark is expected to (a) appear with age, (b) accelerate ageing when experimentally worsened, and (c) slow ageing when repaired.

A map of the twelve hallmarks (grouped):

PRIMARY (the damage itself):

• Genomic instability
• Telomere attrition
• Epigenetic alterations
• Loss of proteostasis

ANTAGONISTIC (responses that turn harmful):

• Deregulated nutrient sensing
• Mitochondrial dysfunction
• Cellular senescence

INTEGRATIVE (phenotype) — emerging from the primary and antagonistic hallmarks:

• Stem cell exhaustion
• Altered intercellular communication (including "inflammaging")
• Disabled macroautophagy [added in 2023]
• Chronic inflammation [added in 2023]
• Dysbiosis (microbiome) [added in 2023]

The hallmarks are deeply interconnected: correcting one often improves the others as well. This is precisely why single-target "magic bullets" have fallen short of expectations.

The hallmarks in detail

Genomic instability / DNA damage. Across a lifetime, DNA accumulates mutations and lesions from replication errors, reactive oxygen species and environmental mutagens, while repair capacity declines with age. Progeroid ("accelerated ageing") syndromes such as Werner and Hutchinson–Gilford progeria arise from defects in genome maintenance and provide strong causal evidence linking DNA damage to ageing phenotypes (López-Otín et al., 2013).

Telomere attrition. Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. Critically short telomeres trigger senescence or apoptosis. The relationship, however, is more nuanced than it appears: telomerase reactivation carries cancer risk, and human Mendelian randomisation data suggest that longer telomeres lower some cardiovascular risks while raising cancer risk. At the individual level, telomere length is a weak and noisy biomarker.

Epigenetic alterations. DNA methylation patterns, histone modifications and chromatin architecture drift with age, changing which genes are expressed without altering the DNA sequence. This drift is in principle partly reversible and forms the conceptual basis of epigenetic "clocks" and reprogramming approaches (Section 6). The "information theory of ageing" (Yang et al., 2023, Cell) argues that the loss of epigenetic information, not only DNA mutation, is a root cause — an influential but equally contested view.

Loss of proteostasis and disabled autophagy. Cells maintain protein quality through chaperones, the ubiquitin–proteasome system and autophagy (recycling of damaged components). These mechanisms decline with age and allow toxic aggregates (e.g. amyloid-β, tau, α-synuclein) to accumulate — which lies at the very centre of neurodegeneration. Inducing autophagy (through fasting, exercise, spermidine or mTOR inhibition) is one of the field's leading intervention themes.

Deregulated nutrient sensing. The principal integrator of longevity biology. Four interacting pathways sit at the heart of it: nutrient/amino acid/insulin and IGF-1 signals drive the IIS/IGF-1 (growth) and mTORC1 (growth, protein synthesis) pathways; while in low-energy states AMPK activates autophagy and mitochondrial biogenesis, FOXO (stress resistance, longevity genes) is inhibited by IIS/mTOR, and NAD⁺-dependent SIRT1 supports stress resistance, mitochondrial and metabolic health.

• mTOR (mechanistic target of rapamycin): senses amino acid and growth signals; drives protein synthesis and cell growth. Inhibition of mTORC1 (via rapamycin or CR) extends lifespan across species — the single most robust pharmacological result in ageing biology.
• AMPK: a low-energy sensor; activated by exercise and metformin, it supports autophagy and mitochondrial health.
• IGF-1 / insulin signalling (IIS): reduced IIS extends lifespan in worms, flies and mice; genetic variants that lower IGF-1 are enriched among centenarians (Milman et al., 2014). Yet IGF-1 is also necessary for muscle and brain — so this is a trade-off, not a simple "the lower the better".
• FOXO transcription factors: activated when IIS/mTOR is low; they switch on stress resistance and repair genes. FOXO3 variants are among the most reproducibly replicated genes associated with human longevity (Willcox et al., 2008).
• Sirtuins (SIRT1–7): NAD⁺-dependent enzymes that regulate metabolism, DNA repair and inflammation. They sit at the centre of the resveratrol/NAD⁺ story — promising mechanism, but weak human outcome data.

Mitochondrial dysfunction. Mitochondria produce energy, but in doing so they also generate reactive oxygen species; their efficiency declines with age and mtDNA damage accumulates. The simple "free radical theory" has now been superseded — antioxidant supplements generally do not extend life and may even blunt the benefits of exercise. Mitochondrial signalling and quality control (mitophagy) are more decisive than raw oxidative damage.

Cellular senescence. Damaged cells can enter a permanently non-dividing state; while resisting death, they secrete inflammatory factors (the senescence-associated secretory phenotype, SASP). Even a few senescent cells can poison the surrounding tissue. Clearing them ("senolytics") reverses many ageing phenotypes in mice (Baker et al., 2016; Xu et al., 2018), which is why it is a prominent intervention target (Sections 4 and 5).

Stem cell exhaustion. Tissue-specific stem cells decline in number and function with age, impairing repair (blood, muscle, gut, brain). It is in part a consequence of the other hallmarks.

Altered intercellular communication and inflammaging. Ageing tissues drift towards a chronic, sterile, low-grade inflammation ("inflammaging"), driven in part by senescent cells, gut permeability and immune changes. Chronic inflammation predicts both frailty and mortality and is a plausible common driver (Furman et al., 2019).

Dysbiosis (microbiome). The gut microbiome shifts with age towards reduced diversity and more pro-inflammatory species. Germ-free and faecal transplant experiments in mice show that the microbiome can transfer some ageing phenotypes; causal evidence in humans, however, is still at an early stage.

Immune ageing (immunosenescence + inflammaging). Thymic involution reduces the production of new T cells; immune surveillance against infection, cancer and senescent cells declines. The steep age gradient of COVID-19 mortality is a striking example. Restoring immune function (e.g. through thymic regeneration or reprogramming) is an active target.

Lifestyle Interventions

We address each intervention in terms of its mechanism, evidence, rough effect size and risks. These are the interventions with the best human evidence and the best benefit-to-risk ratio.

Exercise — the closest thing to a longevity "drug"

Cardiorespiratory fitness (VO₂max). One of the strongest known predictors of all-cause mortality. In a retrospective study of more than 120,000 people undergoing treadmill testing, higher fitness was associated with progressively lower mortality with no observed ceiling; being in the lowest fitness category carried a mortality risk comparable to — and even exceeding — smoking, diabetes or coronary disease (Mandsager et al., 2018, JAMA Network Open). High fitness is associated with a marked reduction in all-cause mortality (observationally, roughly a 0.2–0.5 hazard ratio); the largest absolute gain is obtained in moving from "low fitness" to "below average".

• Mechanism: increased mitochondrial density/function, insulin sensitivity, endothelial/vascular health, AMPK activation, autophagy, anti-inflammatory myokines, cardiac output.
• Effect size: large. Observationally, high versus low fitness is associated with roughly a 0.2–0.5 hazard ratio for mortality; even modest increases in fitness meaningfully lower risk.

Zone 2 training (moderate, conversational-pace aerobic work) improves mitochondrial density and fat oxidation; it is also the foundation of aerobic capacity. HIIT (high-intensity intervals) raises VO₂max efficiently and may be particularly beneficial for mitochondrial function in older adults. A combination that works well in practice is this: a predominance of Zone 2 volume, with a smaller amount of high-intensity work on top.

Resistance training, muscle mass and grip strength. Strength and muscle are independently protective. Grip strength is a remarkably strong and simple predictor of all-cause and cardiovascular mortality (Leong et al., 2015, The Lancet). Preserving muscle prevents sarcopenia (age-related muscle loss), maintains metabolic health, and prevents falls and fractures — among the leading causes of disability and death in older people.

• Effect size: in large international cohorts, every ~5 kg of lower grip strength is associated with significantly higher mortality.

The practical implication is this: both aerobic fitness and strength matter, and they predict mortality somewhat independently of one another. This is probably the single highest-yield section of the report.

Nutrition

The Mediterranean diet. The best-evidenced dietary pattern. The PREDIMED randomised trial found that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events in high-risk adults compared with a control diet (Estruch et al., 2018, NEJM — republished after re-analysis). The emphasis is on vegetables, legumes, fruit, whole grains, olive oil, nuts and fish, with low intake of red/processed meat and refined sugar.

• Mechanism: anti-inflammatory effect, improved lipid and endothelial function, polyphenols, fibre/microbiome.
• Effect size: ~30% relative reduction in major CV events in a high-risk RCT population.

Blue Zones. Regions reported to harbour large numbers of centenarians (Okinawa, Sardinia, Ikaria, Nicoya, Loma Linda) share a common denominator of plant-based eating, daily movement, social integration and purpose. There is an important caveat, however: the Blue Zones concept is observational and increasingly contested — some apparent longevity clusters may reflect incomplete birth records, pension fraud or statistical artefacts (Newman, 2024, preprint/analysis). It is more accurate to read the Blue Zones not as evidence but as a hypothesis-generating lifestyle inspiration.

Caloric restriction (CR). Reducing calories without causing malnutrition robustly extends lifespan in many species. The human RCT CALERIE randomised 220 non-obese adults to ~25% CR (~12% was actually achieved) or a normal diet for 2 years; CR improved cardiometabolic risk factors, reduced markers of inflammation and cellular senescence, and slowed the DunedinPACE pace-of-ageing clock by approximately 3% (Waziry et al., 2023, Nature Aging). In other cohorts a 3% slower pace of ageing is associated with a ~15% lower risk of death — suggestive, but not proof of a mortality benefit.

Intermittent fasting (IF) and time-restricted eating (TRE). Popular approaches adjacent to CR. The evidence here is mixed: some studies show that TRE helps with weight loss and glucose control, but head-to-head RCTs frequently fail to find TRE superior to simple calorie reduction for weight and metabolic outcomes. The benefit most likely comes from reduced total intake rather than any "magic of timing". Extended fasting and fasting-mimicking diets (Longo's work) show metabolic effects but lack long-term human outcome data.

Protein intake. A genuine point of tension in the field. High protein supports muscle and counters sarcopenia (something that becomes especially important with age); on the other hand, chronically high protein (particularly animal protein rich in methionine/leucine) raises mTOR/IGF-1 and could theoretically accelerate ageing. The practical synthesis runs as follows: protein requirements increase with age (~1.0–1.6 g/kg/day is often cited for older adults), and for most people over ~50 the preservation of muscle outweighs theoretical mTOR concerns. Young individuals with ample muscle have more flexibility to keep protein periodically lower.

Sleep

Chronically short (<6 hours) or poor-quality sleep is associated with higher all-cause mortality, cardiovascular disease, diabetes, obesity and dementia. During sleep, the glymphatic clearance of brain waste (including amyloid-β), immune regulation and metabolic control take place. Both too little and consistently too much sleep are followed by worse outcomes (a U-shaped relationship). The effect size is substantial and causally plausible; sleep is a fundamental, high-yield and low-risk target.

Stress, mental health and social connection

Chronic psychological stress accelerates markers of biological ageing, increases inflammation and worsens cardiometabolic risk.

Social connection is a robust predictor of mortality: a landmark meta-analysis found that weak social relationships were associated with a ~50% higher likelihood of death — an effect comparable to smoking and exceeding obesity (Holt-Lunstad et al., 2010, PLoS Medicine). Loneliness is a serious and underestimated health risk.

Mental health: depression and anxiety independently increase cardiovascular and mortality risk; purpose/meaning ("ikigai") is associated with longevity in cohort studies.

Thermal stress

Sauna. Prospective Finnish cohort data associate frequent sauna use (4–7 times per week) with lower cardiovascular and all-cause mortality compared with once per week; in some Finnish cohorts frequent sauna use is linked to more than 40% lower cardiovascular mortality (Laukkanen et al., 2015, JAMA Internal Medicine). Plausible mechanisms include heat-shock proteins, improved endothelial/vascular function and an exercise-like cardiovascular response. The data are observational, so residual confounding may well be at play, but the effect is biologically plausible and low-risk (cautions: dehydration, alcohol, pregnancy, unstable heart disease).

Cold exposure. Popular, but the evidence for longevity is weak. There may be plausible effects on brown fat, mood and inflammation; human outcome data are absent. In short, modest and speculative; risks include cardiovascular stress in susceptible individuals.

Smoking and alcohol

Smoking: by far the largest modifiable killer. Quitting at any age adds years and reverses much of the risk over time. There is no safe level. For a smoker, this is the single highest-impact behaviour change.

Alcohol: the old "J-curve" (light drinking being protective) is now largely attributed to study design flaws (misclassification of former drinkers/those who quit because of illness). Large analyses conclude that the safest level for overall health is zero, with risk rising steadily above it (GBD Alcohol Collaborators, 2018, The Lancet). Any cardiovascular signal at low intake is offset at the population level by cancer and injury risk.

Longevity Supplements

A few honest points stand out. In the NAD⁺ story, NMN and NR reliably raise blood NAD⁺, yet a 2025 meta-analysis of RCTs found no improvement in muscle mass, strength or physical function in older adults — the classic "blood NAD⁺ ↑ ≠ function improved" problem (see Section 12). Taurine, meanwhile, is a good cautionary example of hype meeting replication: the flashy 2023 Science paper was largely refuted by 2025 human data. Resveratrol, too, despite launching the sirtuin-supplement industry, has repeatedly fallen short of expectations in humans.

Pharmaceutical Interventions

Metformin

Approved for: Type 2 diabetes (over 60 years of use); not approved for ageing.

Mechanism: indirect AMPK activation, reduced hepatic glucose production, modulation of mitochondrial complex I, anti-inflammatory effects.

Evidence: It extends lifespan in some mouse studies; a 2024 Cell study reported that metformin slowed ageing markers in male monkeys (Yang et al., 2024). Human observational data (diabetics on metformin sometimes outliving non-diabetic controls) are provocative but open to confounding. The key trial in the field, TAME (~3,000 adults), is designed to test whether metformin delays the onset of age-related disease; as of 2026, however, it remains only partly funded and there is as yet no efficacy result. Moreover, there is a worrying signal: metformin may blunt exercise-induced gains in muscle and fitness (the MASTERS trial); and the 2025 MET-PREVENT trial found no functional benefit in pre-frail older adults, along with worse tolerability.

Risks: GI discomfort, B12 deficiency, rare lactic acidosis (in kidney disease).

Expert opinion: Divided. Barzilai defends its geroprotective promise; Kaeberlein and others warn that the exercise-blunting effect may make metformin a poor choice for healthy, active people.

Rapamycin (sirolimus) and everolimus

Approved for: Rapamycin — immunosuppression in organ transplantation, some cancers, lymphangioleiomyomatosis. Everolimus — cancers, transplantation. Not approved for ageing.

Mechanism: mTORC1 inhibition — the most robust longevity pathway.

Evidence: Rapamycin is the drug that most reproducibly extends lifespan in mice; it works even when started late in life, and across independent laboratories (Harrison et al., 2009, Nature; NIA ITP). A rapamycin analogue (everolimus, at low intermittent dosing) improved vaccine responses in older people, suggesting a form of immune rejuvenation (Mannick et al., 2014, Science Translational Medicine). The crowdfunded PEARL trial (48 weeks, ~114 completers, low weekly doses) found low-dose rapamycin to be safe; there were no serious adverse events and there were signals of improvement in muscle (women) and bone (men) on DEXA, although the effects were variable and modest, and compounded rapamycin was also absorbed less than expected (Zalzala/Harinath et al., 2024, medRxiv/Aging).

Risks: dose-dependent immunosuppression, mouth ulcers, impaired glucose tolerance/lipid derangement, delayed wound healing. Low intermittent dosing aims to minimise these, but long-term safety in healthy people is unproven.

Expert opinion: It is regarded as the scientifically most convincing geroprotector; nonetheless, experts stress that human evidence of a healthspan benefit is not yet available. The Dog Aging Project (TRIAD trial) is testing rapamycin in companion dogs as a translational bridge.

SGLT2 inhibitors (canagliflozin, empagliflozin)

Approved for: Type 2 diabetes, heart failure, chronic kidney disease.

Mechanism: increases urinary glucose excretion and blunts glucose peaks; metabolic and possibly direct organ-protective effects.

Evidence: Canagliflozin extended median lifespan by ~14% in male (but not female) mice in the NIA ITP (Miller et al., 2020, JCI Insight). In humans (with diabetes/heart/kidney disease), this class has strong hard-outcome data for cardiovascular and renal protection. Its longevity use in healthy people, however, is speculative.

Risks: genital/urinary infections, rare ketoacidosis, dehydration/hypotension.

GLP-1 receptor agonists (semaglutide, tirzepatide) — the most important recent development

Approved for: Type 2 diabetes; obesity; semaglutide is additionally approved (2024) to reduce cardiovascular events in overweight/obese patients with established CV disease.

Mechanism: incretin signalling → reduced appetite/weight, glucose control; in addition, weight-independent anti-inflammatory, vascular, cardiac, renal and possibly neuroprotective effects (GLP-1 receptors are widespread).

Evidence: The SELECT trial (17,604 non-diabetic patients with obesity + CVD) showed a 20% reduction in major cardiovascular events with semaglutide (Lincoff et al., 2023, NEJM); importantly, the benefit emerged before substantial weight loss — pointing to mechanisms beyond weight. Tirzepatide reduced heart failure events (SUMMIT) and shows large metabolic effects. A 2025 randomised sub-study found that semaglutide slowed multiple epigenetic ageing clocks within 32 weeks (e.g. DunedinPACE ~9% slower). Large real-world datasets suggest lower all-cause mortality, stroke and possibly dementia risk. The $38M ARPA-H "VITAL-H" trial, testing semaglutide directly for healthspan extension, begins around 2026.

Risks: nausea/GI effects, muscle loss alongside fat loss (mitigate with protein + resistance training), pancreatitis (rare), gallbladder disease; contraindicated with a personal/family history of medullary thyroid carcinoma/MEN2; weight regain on discontinuation.

Expert opinion: Increasingly seen as the first genuinely disease-modifying "metabolic geroprotector" with hard human outcome data; even so, the "anti-aging" framing has run ahead of the direct evidence.

Acarbose

Approved for: Type 2 diabetes (blunts post-meal glucose by slowing carbohydrate digestion).

Evidence: Extended mouse lifespan in the ITP, more markedly in males (Harrison et al., 2014). No human longevity data.

Risks: flatulence, GI discomfort (from carbohydrate fermentation).

Low-dose aspirin

Approved for: Secondary cardiovascular prevention.

Evidence in healthy older people: The large ASPREE RCT found that low-dose aspirin did not prolong disability-free survival in healthy older adults and increased major bleeding (McNeil et al., 2018, NEJM). This result reversed routine primary-prevention use.

Statins

Approved for: Lipid lowering / cardiovascular prevention.

Evidence: Strong for reducing cardiovascular events and mortality in at-risk populations by lowering ApoB/LDL. Because atherosclerotic cardiovascular disease is the leading killer, appropriate lipid management is genuinely "pro-longevity".

Risks: myalgia (a common complaint, often nocebo in blinded trials), rare myopathy, a small increase in diabetes incidence, transient liver enzyme changes.

Senolytics

Dasatinib + Quercetin (D+Q): Dasatinib is an approved leukaemia drug; the combination is investigational for ageing. In humans, D+Q reduced the burden of senescent cells in adipose tissue in diabetic kidney disease (Hickson et al., 2019, EBioMedicine) and has produced signals in osteoporosis and other pilot studies; multiple trials are ongoing (e.g. STAMINA for Alzheimer's risk). The agents are given as short intermittent "hit-and-run" courses.

Fisetin: a flavonoid senolytic in human trials (e.g. Mayo Clinic, osteoarthritis NCT04210986); human efficacy data are still pending.

NAD⁺ boosters (as pharmaceuticals)

Pharmaceutical-grade NMN (e.g. MIB-626) and NR safely raise NAD⁺; but, as with the supplements, they have not demonstrated a functional/healthspan benefit in controlled human studies (see Sections 4 and 12).

Regenerative Medicine

Stem cells and mesenchymal stromal cells (MSCs). MSCs (often called "mesenchymal stem cells") are studied for their anti-inflammatory, immunomodulatory and paracrine (secreted factor) effects rather than for genuine tissue replacement. There are some signals in osteoarthritis, GVHD and inflammatory conditions; by contrast, most commercial anti-aging "stem cell" infusions are unproven and at times dangerous. Quality, sourcing and regulation vary enormously.

Induced pluripotent stem cells (iPSCs). Adult cells reprogrammed into an embryonic-like state (Yamanaka, 2006). They are fundamental to regenerative medicine and disease modelling; although their direct anti-aging use is at an early stage, they provide the foundation for the reprogramming approaches described below.

Gene therapy and CRISPR. Gene editing is transforming specific genetic diseases (e.g. approved treatments for sickle cell disease). On the aging side, targets include telomerase, follistatin (muscle), Klotho and others — but most remain preclinical. Direct-to-consumer "longevity gene therapy" offered abroad is scientifically premature and ethically problematic.

Epigenetic (partial) reprogramming — the frontier. Transient expression of the Yamanaka factors (OSKM/OSK) can reset epigenetic age without erasing cell identity. In mice, partial reprogramming reversed markers of aging (Ocampo et al., 2016, Cell), restored vision by rejuvenating optic nerve neurons (Lu et al., 2020, Nature), and in 2024–2025 studies targeted "mesenchymal drift" and extended lifespan in old mice (Paine et al., 2024, Aging Cell; Izpisua Belmonte group, 2025, Cell). Altos Labs (~$3 billion) and Retro Biosciences are pursuing this; Life Biosciences obtained FDA IND clearance for a reprogramming-based ophthalmic therapy (ER-100).

Exosomes. Cell-secreted vesicles carrying a signalling cargo; they are studied both as the "active ingredient" of stem-cell effects and as a delivery vehicle. Commercial exosome products are largely unregulated and unproven.

Young plasma, plasma exchange and heterochronic approaches. These approaches derive from parabiosis experiments (joining the circulations of young and old mice) that showed systemic factors influence aging (Conboy et al., 2005). The human studies are as follows:

• "Old plasma dilution" / therapeutic plasma exchange (TPE) aims to remove pro-aging factors rather than to add "young blood". A 2025 randomised, placebo-controlled Buck Institute study reported that TPE (particularly TPE + IVIG) lowered multi-omic biological age by an average of up to ~2.6 years (Fuentealba et al., 2025, Aging Cell) — early, small, surrogate-endpoint data.
• Commercial young-plasma infusions (e.g. the former Ambrosia model) lack rigorous evidence of efficacy; the FDA has warned against such offerings.

Tissue engineering and organ printing. 3D bioprinting of tissues and ultimately organs could solve the transplant shortage and age-related organ failure. Simple tissues (skin, cartilage) are advancing; complex vascularised organs are years away. Ex vivo organ rejuvenation (reprogramming donor organs before transplantation) is being explored as a nearer-term application.

Biomarkers and Diagnostics

Measuring "biological age" and risk allows people to track interventions — but most aging clocks are not yet validated for individual decision-making or as a regulatory trial endpoint.

Epigenetic clocks (DNA methylation)

These clocks have a number of limitations: technical noise, tissue specificity (usually blood) and uncertain causality (do the clocks measure damage, or merely a correlation?). A clock reading is not a verdict; change over time and validated versions are far more meaningful than a single number from a consumer test.

Functional / physiological markers (often more actionable than the clocks)

• VO₂max (cardiorespiratory fitness): one of the strongest predictors of mortality — and directly trainable on top of that.
• Grip strength / muscle strength: a strong and simple predictor of mortality.
• Gait speed, chair rise, balance: predict frailty and mortality in older adults.
• DEXA scan: body composition — bone mineral density (osteoporosis risk), lean mass (sarcopenia) and metabolically dangerous visceral fat.

Cardiometabolic blood/imaging markers (high clinical value)

• ApoB: atherogenic particle count; probably superior to standard LDL-C for cardiovascular risk.
• Lp(a): largely genetic, an independent risk factor for CVD/aortic stenosis; measuring it once in a lifetime is sufficient.
• Coronary artery calcium (CAC) score: a direct CT-based measure of coronary atherosclerosis; powerful for personalising prevention.
• HbA1c, fasting insulin, glucose and continuous glucose monitoring (CGM): assess glycaemic control and insulin resistance (a fundamental driver of aging). CGM also provides real-time dietary feedback.
• hs-CRP: a marker of systemic inflammation ("inflammaging"); predicts cardiovascular risk.

To set out a practical hierarchy: for most people, validated cardiometabolic markers (ApoB, Lp(a), CAC, HbA1c, blood pressure) together with fitness/strength testing offer far more actionable value today than consumer epigenetic-clock tests.

Clinical Trials to Watch

One comment: the credibility of the field depends on moving from surrogate endpoints (clocks, biomarkers) to hard endpoints (function, disease incidence, mortality). In that respect, TAME's regulatory design and the hard-outcome data for GLP-1s are the most important near-term developments.

Leading Researchers: Contributions, Consensus, Disagreements

There is broad consensus that aging is modifiable; that lifestyle (exercise, nutrition, metabolic health) is foundational; that mTOR/nutrient-sensing biology is central; and that better biomarkers and rigorous human trials are urgently needed.

Disagreement, meanwhile, clusters around the following points: the value of metformin and NAD⁺ boosters; how close "radical" life extension actually is; how far epigenetic clocks can be trusted; and how aggressively unproven interventions may be promoted to the public.

Future Technologies

• AI drug discovery. Machine learning (e.g. Insilico Medicine, Retro Biosciences) accelerates target identification and molecule design; AlphaFold-class structural prediction is reshaping biology. The promise is real, but clinical validation lags behind the hype.
• Digital twins. Computational models of an individual's physiology used to simulate interventions before trying them; early stage and highly data-hungry.
• Whole-body MRI. Screening may catch some cancers/aneurysms early, but it also generates incidentalomas (false alarms, overdiagnosis, anxiety, cascades of further testing). Its value for asymptomatic people is debated.
• Continuous biomonitoring. Wearables and CGMs provide real-time, personalised feedback; the real challenge is translating that data into validated, outcome-improving action.
• Nanomedicine. Targeted drug delivery, senolytic nanoparticles, in-body sensors — largely preclinical.
• Longevity escape velocity (LEV). The hypothesis that therapies could eventually add more than one year to remaining life expectancy for every year of research, thereby outpacing aging. A motivating idea (de Grey), but speculative; most mainstream researchers consider specific timelines unfounded.
• Precision / personalised longevity. Combining genomics, biomarkers and AI to tailor interventions — the field's plausible medium-term direction; contingent on validated biomarkers and trials.
• Aging clocks (next generation). Multi-omic and organ-specific clocks aim to localise aging (e.g. "young heart, old kidney") and could enable targeted intervention and better trial endpoints.

Ranking the Evidence (GRADE-Style Synthesis)

GRADE grades the certainty of evidence as High → Moderate → Low → Very Low, integrating study design, consistency, directness and precision. The categories below are adapted from it. (They apply specifically to "ageing/longevity" outcomes; some interventions are graded higher for their approved disease indications.)

Safety, Interactions and Regulatory Status

A few general principles hold. Prescription geroprotectors used off-label carry the drug's full risk profile without any proven ageing benefit. Supplements are lightly regulated for quality and not at all for efficacy claims; "natural" does not mean safe or effective. Polypharmacy (stacking multiple agents) both multiplies interaction risk and obscures which agent is responsible for any effect.

As for the regulatory landscape: the FDA does not currently recognise ageing as a disease/indication — precisely the barrier TAME was designed to overcome. The EMA is likewise structured around specific diseases. This shapes the entire field: agents reach people mainly through approved disease indications or via off-label and supplement channels.

Actionable Recommendations: A Prioritised Roadmap

Priority ranking by benefit-to-risk for a general adult (highest first):

1. Do not smoke; minimise alcohol. (Highest impact, no downside.)
2. Build and maintain cardiorespiratory fitness. Regular aerobic training (mostly moderate "Zone 2", with some high intensity). Aim to move VO₂max out of the low-fitness range.
3. Do resistance training; preserve muscle and strength. Two to four times per week; it protects against sarcopenia, falls and metabolic decline.
4. Eat a whole-food, plant-forward Mediterranean-style diet; get adequate protein (more with age); limit ultra-processed foods and refined sugar.
5. Prioritise sleep (7–9 hours, a consistent schedule, good sleep hygiene).
6. Manage cardiometabolic risk with a physician: blood pressure, ApoB/LDL, glucose/HbA1c; find out your Lp(a) level (once) and your CAC score if indicated.
7. Nurture strong social ties and mental health; manage chronic stress.
8. Where appropriate, consider low-risk, evidence-plausible adjuncts (e.g. correcting vitamin D/omega-3/magnesium deficiency; creatine for muscle; sauna if accessible).
9. Approach unproven drugs and supplements with scepticism and only under medical guidance; stay away from predatory "anti-aging" clinics.

Benefit–risk snapshot

Emphasis by age band (the fundamentals apply to everyone; the emphasis shifts)

20–35 — Build the foundation and create peak reserve.

• Acquire lifelong exercise habits; maximise peak muscle mass and VO₂max (these are your buffer for later).
• Establish sleep, nutrition and social habits; avoid smoking and excess alcohol; protect your skin from the sun and your hearing from noise.
• Baseline laboratory tests; measure Lp(a) once. Establish mental health fundamentals.
• Supplements/drugs: generally unnecessary beyond correcting deficiencies. Do not chase geroprotector hype.

35–50 — Protect metabolic health; catch risk early.

• Maintain fitness and muscle; resist midlife weight/visceral-fat gain and insulin resistance.
• Monitor ApoB, blood pressure, HbA1c/fasting insulin; discuss a CAC score if CV risk factors are present.
• Prioritise sleep amid career and family demands; manage stress.
• Consider evidence-based adjuncts (omega-3/vitamin D if deficient; creatine). If you are interested in off-label options, speak with a physician who follows the literature.

50–65 — Prevent disease; preserve function.

• Protect muscle and bone aggressively (resistance training + adequate protein; DEXA for bone density).
• Optimise cardiometabolic risk; cancer screening per guidelines; consider statin/lipid therapy if ApoB/risk warrants it.
• This is the age band in which GLP-1 agonists (for appropriate metabolic indications) and other prescription geroprotectors are most actively discussed — with a physician, weighing the real risks (e.g. muscle loss) against the benefits.
• Pay attention to hearing, vision and cognitive/social engagement.

65+ — Maximise healthspan, independence and resilience.

• The emphasis shifts to preventing frailty, falls and functional decline: strength, balance, gait speed, protein adequacy, bone health.
• Vaccinations (immunosenescence makes infections more lethal); polypharmacy review (deprescribe where possible).
• Avoid low-dose aspirin for primary prevention (ASPREE); reassess all supplements for interactions.
• Sustain social connection and cognitive engagement; screen for and treat depression, sensory loss and malnutrition.

Outlook

The credibility of the coming decade will rest on hard human endpoints. The most likely near-term gains fall into three groups: (a) metabolic drugs showing multi-organ, plausibly ageing-related benefits backed by real outcome data (the GLP-1 class); (b) better, validated biomarkers that accelerate trials (pace-of-ageing and organ-specific clocks); and (c) senolytics, which will prove or disprove themselves in targeted diseases. The high-ceiling but high-uncertainty bets are partial epigenetic reprogramming and systemic rejuvenation (plasma/blood-factor approaches); the mouse data are striking, yet safety and efficacy in humans are not yet established. Meanwhile the unglamorous truth persists: the interventions with the best evidence are the ones your grandparents could have named. And the field's real task is to add rigorously proven tools on top of that foundation — not to sell shortcuts around it.

References

1. Baker, D. J., Childs, B. G., Durik, M., et al. (2016). Naturally occurring p16^Ink4a^-positive cells shorten healthy lifespan. Nature, 530(7589), 184–189. https://doi.org/10.1038/nature16932
2. Belsky, D. W., Caspi, A., Corcoran, D. L., et al. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife, 11, e73420. https://doi.org/10.7554/eLife.73420
3. Conboy, I. M., Conboy, M. J., Wagers, A. J., et al. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature, 433(7027), 760–764. https://doi.org/10.1038/nature03260
4. Estruch, R., Ros, E., Salas-Salvadó, J., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New England Journal of Medicine, 378(25), e34. https://doi.org/10.1056/NEJMoa1800389
5. Fernandez, M. E., de Cabo, R., et al. (2025). Is taurine an aging biomarker? Science.
6. Fuentealba, M., Kiprov, D., Schneider, K., et al. (2025). Multi-omics analysis reveals biomarkers that contribute to biological age rejuvenation in response to single-blinded randomized placebo-controlled therapeutic plasma exchange. Aging Cell. https://doi.org/10.1111/acel.70103
7. Furman, D., Campisi, J., Verdin, E., et al. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0
8. GBD 2016 Alcohol Collaborators. (2018). Alcohol use and burden for 195 countries and territories, 1990–2016. The Lancet, 392(10152), 1015–1035. https://doi.org/10.1016/S0140-6736(18)31310-2
9. Harrison, D. E., Strong, R., Sharp, Z. D., et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460(7253), 392–395. https://doi.org/10.1038/nature08221
10. Harrison, D. E., Strong, R., Allison, D. B., et al. (2014). Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell, 13(2), 273–282. https://doi.org/10.1111/acel.12170
11. Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine, 47, 446–456. https://doi.org/10.1016/j.ebiom.2019.08.069
12. Holt-Lunstad, J., Smith, T. B., ve Layton, J. B. (2010). Social relationships and mortality risk: A meta-analytic review. PLoS Medicine, 7(7), e1000316. https://doi.org/10.1371/journal.pmed.1000316
13. Kennedy, B. K., Berger, S. L., Brunet, A., et al. (2014). Geroscience: Linking aging to chronic disease. Cell, 159(4), 709–713. https://doi.org/10.1016/j.cell.2014.10.039
14. Laukkanen, T., Khan, H., Zaccardi, F., ve Laukkanen, J. A. (2015). Association between sauna bathing and fatal cardiovascular and all-cause mortality events. JAMA Internal Medicine, 175(4), 542–548. https://doi.org/10.1001/jamainternmed.2014.8187
15. Leong, D. P., Teo, K. K., Rangarajan, S., et al. (2015). Prognostic value of grip strength: Findings from the PURE study. The Lancet, 386(9990), 266–273. https://doi.org/10.1016/S0140-6736(14)62000-6
16. Levine, M. E., Lu, A. T., Quach, A., et al. (2018). An epigenetic biomarker of aging for lifespan and healthspan (PhenoAge). Aging, 10(4), 573–591. https://doi.org/10.18632/aging.101414
17. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
18. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., ve Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194–1217. https://doi.org/10.1016/j.cell.2013.05.039
19. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., ve Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278. https://doi.org/10.1016/j.cell.2022.11.001
20. Lu, A. T., Quach, A., Wilson, J. G., et al. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging, 11(2), 303–327. https://doi.org/10.18632/aging.101684
21. Lu, Y., Brommer, B., Tian, X., et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature, 588(7836), 124–129. https://doi.org/10.1038/s41586-020-2975-4
22. Mandsager, K., Harb, S., Cremer, P., et al. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 1(6), e183605. https://doi.org/10.1001/jamanetworkopen.2018.3605
23. Mannick, J. B., Del Giudice, G., Lattanzi, M., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 6(268), 268ra179. https://doi.org/10.1126/scitranslmed.3009892
24. Marcangeli, V., et al. (2025). Experimental evidence against taurine deficiency as a driver of aging in humans. Aging Cell. https://doi.org/10.1111/acel.70191
25. McNeil, J. J., Nelson, M. R., Woods, R. L., et al. (2018). Effect of aspirin on disability-free survival in the healthy elderly (ASPREE). New England Journal of Medicine, 379(16), 1499–1508. https://doi.org/10.1056/NEJMoa1800722
26. Miller, R. A., Harrison, D. E., Allison, D. B., et al. (2020). Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight, 5(21), e140019. https://doi.org/10.1172/jci.insight.140019
27. Milman, S., Atzmon, G., Huffman, D. M., et al. (2014). Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell, 13(4), 769–771. https://doi.org/10.1111/acel.12213
28. Nadon, N. L., Strong, R., Miller, R. A., ve Harrison, D. E. (2017). NIA Interventions Testing Program. EBioMedicine, 21, 3–4. https://doi.org/10.1016/j.ebiom.2016.11.038
29. Ocampo, A., Reddy, P., Martinez-Redondo, P., et al. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell, 167(7), 1719–1733.e12. https://doi.org/10.1016/j.cell.2016.11.052
30. Paine, P. T., et al. (2024). Partial cellular reprogramming: A deep dive into an emerging rejuvenation technology. Aging Cell, 23(2), e14039. https://doi.org/10.1111/acel.14039
31. Singh, P., Gollapalli, K., Mangiola, S., et al. (2023). Taurine deficiency as a driver of aging. Science, 380(6649), eabn9257. https://doi.org/10.1126/science.abn9257
32. Waziry, R., Ryan, C. P., Corcoran, D. L., et al. (2023). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging, 3(3), 248–257. https://doi.org/10.1038/s43587-022-00357-y
33. Willcox, B. J., Donlon, T. A., He, Q., et al. (2008). FOXO3A genotype is strongly associated with human longevity. PNAS, 105(37), 13987–13992. https://doi.org/10.1073/pnas.0801030105
34. Xu, M., Pirtskhalava, T., Farr, J. N., et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine, 24(8), 1246–1256. https://doi.org/10.1038/s41591-018-0092-9
35. Yang, J.-H., Hayano, M., Griffin, P. T., et al. (2023). Loss of epigenetic information as a cause of mammalian aging. Cell, 186(2), 305–326.e27. https://doi.org/10.1016/j.cell.2022.12.027
36. Yang, Y., et al. (2024). Metformin decelerates aging clock in male monkeys. Cell, 187(22), 6358–6378.e29. https://doi.org/10.1016/j.cell.2024.08.021
37. Zalzala, S., Harinath, G., Lee, V., et al. (2024). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. medRxiv / Aging. https://doi.org/10.1101/2024.08.21.24312372